CORCEPT THERAPEUTICS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.52 USD | -1.15% |
|
-4.71% | -15.27% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With a 2024 P/E ratio at 28.61 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 3.49 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.27% | 2.87B | C- | ||
| +38.51% | 727B | C+ | ||
| -6.23% | 354B | C+ | ||
| +18.78% | 328B | B- | ||
| +1.35% | 277B | C+ | ||
| +14.58% | 243B | B+ | ||
| +7.59% | 205B | B- | ||
| -5.97% | 203B | A+ | ||
| +6.19% | 164B | C+ | ||
| +0.31% | 164B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CORT Stock
- Ratings Corcept Therapeutics Incorporated
